CureVac N.V. (CVAC)
NASDAQ: CVAC · IEX Real-Time Price · USD
3.340
+0.010 (0.30%)
At close: Jul 2, 2024, 4:00 PM
3.260
-0.080 (-2.40%)
After-hours: Jul 2, 2024, 7:57 PM EDT
CureVac Revenue
CureVac had revenue of $64.13M in the twelve months ending March 31, 2024, with 17.59% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $13.45M with 73.56% year-over-year growth. In the year 2023, CureVac had annual revenue of $59.73M, a decrease of -16.72%.
Revenue (ttm)
$64.13M
Revenue Growth
+17.59%
P/S Ratio
11.68
Revenue / Employee
$64,197
Employees
999
Market Cap
749.18M USD
Revenue Chart
* The company reports in EUR currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 59.73M | -11.99M | -16.72% |
Dec 31, 2022 | 71.72M | -45.31M | -38.72% |
Dec 31, 2021 | 117.03M | 57.44M | 96.37% |
Dec 31, 2020 | 59.60M | 40.03M | 204.56% |
Dec 31, 2019 | 19.57M | 4.77M | 32.27% |
Dec 31, 2018 | 14.79M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Healthcare Services Group | 1.68B |
CareDx | 275.11M |
Ginkgo Bioworks Holdings | 208.70M |
Atrion | 176.67M |
Harrow Health | 138.68M |
Dianthus Therapeutics | 2.26M |
CVAC News
- 8 days ago - CureVac Announces Voting Results of General Meeting - Accesswire
- 2 months ago - CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update - Accesswire
- 2 months ago - CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK - Accesswire
- 2 months ago - CureVac Appoints Thaminda Ramanayake as New Chief Business Officer - Accesswire
- 2 months ago - CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024 - Accesswire
- 2 months ago - CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines - Accesswire
- 3 months ago - CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK - Accesswire
- 6 months ago - CureVac stock gains as COVID vaccine candidates show promise - Market Watch